Abraham Rubinstein

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/580225/publications.pdf

Version: 2024-02-01

94 papers 3,985 citations

35 h-index 123424 61 g-index

102 all docs 102 docs citations

102 times ranked

3985 citing authors

#	Article	IF	CITATIONS
1	Boron Containing Compounds as Protease Inhibitors. Chemical Reviews, 2012, 112, 4156-4220.	47.7	352
2	In vitro evaluation of calcium pectinate: a potential colon-specific drug delivery carrier. Pharmaceutical Research, 1993, 10, 258-263.	3.5	202
3	Microbially controlled drug delivery to the colon. Biopharmaceutics and Drug Disposition, 1990, 11, 465-475.	1.9	149
4	Approaches and Opportunities in Colon-Specific Drug Delivery. Critical Reviews in Therapeutic Drug Carrier Systems, 1995, 12, 101-149.	2.2	144
5	Differential Adhesion of Normal and Inflamed Rat Colonic Mucosa by Charged Liposomes. Pharmaceutical Research, 2004, 21, 447-453.	3.5	122
6	Transferrin as a Luminal Target for Negatively Charged Liposomes in the Inflamed Colonic Mucosa. Molecular Pharmaceutics, 2009, 6, 1083-1091.	4.6	121
7	Phosphated crosslinked guar for colon-specific drug delivery. Journal of Controlled Release, 2000, 63, 121-127.	9.9	115
8	Chondroitin sulfate: A potential biodegradable carrier for colon-specific drug delivery. International Journal of Pharmaceutics, 1992, 84, 141-150.	5.2	108
9	Phosphated crosslinked guar for colon-specific drug delivery. Journal of Controlled Release, 2000, 63, 129-134.	9.9	104
10	Detection of a long non-coding RNA (CCAT1) in living cells and human adenocarcinoma of colon tissues using FIT–PNA molecular beacons. Cancer Letters, 2014, 352, 90-96.	7.2	97
11	Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer–doxorubicin conjugates to human colon cancer cells. European Journal of Cancer, 2004, 40, 148-157.	2.8	95
12	Biocompatibility evaluation of crosslinked chitosan hydrogels after subcutaneous and intraperitoneal implantation in the rat. Journal of Biomedical Materials Research - Part A, 2007, 83A, 414-422.	4.0	94
13	Colonic drug delivery: enhanced release of indomethacin from cross-linked chondroitin matrix in rat cecal content. Pharmaceutical Research, 1992, 09, 276-278.	3.5	91
14	The rationale for peptide drug delivery to the colon and the potential of polymeric carriers as effective tools. Journal of Controlled Release, 1997, 46, 59-73.	9.9	82
15	Crosslinked chitosan implants as potential degradable devices for brachytherapy: In vitro and in vivo analysis. Journal of Controlled Release, 2006, 111, 281-289.	9.9	81
16	Low swelling, crosslinked guar and its potential use as colon-specific drug carrier. Pharmaceutical Research, 1998, 15, 1019-1025.	3.5	80
17	Detection of Endogenous <i>K-ras</i> mRNA in Living Cells at a Single Base Resolution by a PNA Molecular Beacon. Molecular Pharmaceutics, 2012, 9, 685-693.	4.6	80
18	Drug Targeting by Surface Cationization. Critical Reviews in Therapeutic Drug Carrier Systems, 2000, 17, 41.	2.2	77

#	Article	IF	CITATIONS
19	Cross-linked chondroitin sulphate: characterization for drug delivery purposes. Biomaterials, 1995, 16, 473-478.	11.4	75
20	Enhanced Biorecognition and Internalization of HPMA Copolymers Containing Multiple or Multivalent Carbohydrate Side-Chains by Human Hepatocarcinoma Cells. Bioconjugate Chemistry, 2001, 12, 890-899.	3.6	73
21	Mucus gel thickness and turnover in the gastrointestinal tract of the rat: response to cholinergic stimulus and implication for mucoadhesion. Pharmaceutical Research, 1994, 11, 794-799.	3.5	71
22	Local treatment of experimental colitis in the rat by negatively charged liposomes of catalase, TMN and SOD. Journal of Drug Targeting, 2006, 14, 155-163.	4.4	69
23	Differences in the reducing power along the rat GI tract: lower antioxidant capacity of the colon. Molecular and Cellular Biochemistry, 1999, 194, 185-191.	3.1	68
24	The Colon as a Possible Target for Orally Administered Peptide and Protein Drugs. Critical Reviews in Therapeutic Drug Carrier Systems, 2002, 19, 499-552.	2.2	62
25	The use of scintigraphy to provide "proof of concept" for novel polysaccharide preparations designed for colonic drug delivery. Pharmaceutical Research, 1997, 14, 103-107.	3.5	59
26	Enhanced Transferrin Receptor Expression by Proinflammatory Cytokines in Enterocytes as a Means for Local Delivery of Drugs to Inflamed Gut Mucosa. PLoS ONE, 2011, 6, e24202.	2.5	59
27	Gastric Emptying of Nondigestible Solids in the Fasted Dog. Journal of Pharmaceutical Sciences, 1987, 76, 117-122.	3.3	57
28	Natural polysaccharides as targeting tools of drugs to the human colon. Drug Development Research, 2000, 50, 435-439.	2.9	51
29	Colonic drug delivery. Drug Discovery Today: Technologies, 2005, 2, 33-37.	4.0	47
30	The role of galactose, lactose, and galactose valency in the biorecognition of N-(2-hydroxypropyl)methacrylamide copolymers by human colon adenocarcinoma cells. Pharmaceutical Research, 2002, 19, 1114-1122.	3.5	44
31	Luminal delivery and dosing considerations of local celecoxib administration to colorectal cancer. European Journal of Pharmaceutical Sciences, 2006, 28, 204-211.	4.0	44
32	Characterization of crosslinked guar by thermal analysis. Carbohydrate Research, 1999, 316, 6-13.	2.3	41
33	Prevention of tumor recurrence and distant metastasis formation in a breast cancer mouse model by biodegradable implant of 131I-norcholesterol. Journal of Controlled Release, 2007, 123, 116-122.	9.9	39
34	Chitosanâ^Pentaglycineâ^Phenylboronic Acid Conjugate:Â A Potential Colon-Specific Platform for Calcitonin. Bioconjugate Chemistry, 2006, 17, 1000-1007.	3.6	37
35	Absorption enhancement of calcitonin in the rat intestine by carbopol-containing submicron emulsions. International Journal of Pharmaceutics, 1997, 154, 235-243.	5.2	34
36	Rapid Gas Chromatographic Assay for Monitoring Valproic Acid and Valpromide in Plasma. Journal of Pharmaceutical Sciences, 1984, 73, 991-993.	3.3	32

#	Article	IF	CITATIONS
37	Local Prevention of Oxidative Stress in the Intestinal Epithelium of the Rat by Adhesive Liposomes of Superoxide Dismutase and Tempamine. Molecular Pharmaceutics, 2005, 2, 2-11.	4.6	31
38	Pharmacokinetics of valpromide after oral administration of a solution and a tablet to healthy volunteers. European Journal of Clinical Pharmacology, 1984, 27, 501-503.	1,9	30
39	Improved intestinal absorption of sulpiride in rats with synchronized oral delivery systems. Journal of Controlled Release, 2001, 70, 139-147.	9.9	30
40	Migration of Adhesive and Nonadhesive Particles in the Rat Intestine under Altered Mucus Secretion Conditions. Journal of Pharmaceutical Sciences, 1998, 87, 453-456.	3.3	29
41	Synthesis and characterization of near IR fluorescent albumin nanoparticles for optical detection of colon cancer. Materials Science and Engineering C, 2013, 33, 923-931.	7.3	27
42	Relation between colonic inflammation severity and total low-molecular-weight antioxidant profiles in experimental colitis. Digestive Diseases and Sciences, 2000, 45, 1180-1187.	2.3	26
43	Targeting normal and neoplastic tissues in the rat jejunum and colon with boronated, cationic acrylamide copolymers. Journal of Controlled Release, 2005, 106, 14-25.	9.9	26
44	Prevention of oxidative damage in the rat jejunal mucosa by pectin. British Journal of Nutrition, 1993, 69, 789-800.	2.3	25
45	The importance of intestinal residence time of absorption enhancer on drug absorption and implication on formulative considerations. International Journal of Pharmaceutics, 1998, 176, 21-30.	5.2	25
46	Beta-casein nanocarriers of celecoxib for improved oral bioavailability. European Journal of Nanomedicine, $2014, 6, .$	0.6	25
47	Increasing the affinity of cationized polyacrylamide-paclitaxel nanoparticles towards colon cancer cells by a surface recognition peptide. International Journal of Pharmaceutics, 2017, 531, 281-291. The effect of Eudragit RL-100 on the mechanical and mucoadhesion properties of polycarbophil dosage	5.2	25
48	forms1The results reported here form part of the dissertation projects of M.B. and T.Ń., completed in partial fulfilment of the requirements of their respective PhD and MSc degrees at the Hebrew University of Jerusalem. The study has been presented in part at the 22nd International Symposium on Controlled Release of Bioactive Materials, Seattle, WA, 1995.1. Journal of Controlled Release, 1997, 45,	9.9	22
49	57-64. A comparative pharmacokinetic study of valpromide and valproic acid after intravenous administration in humans. International Journal of Pharmaceutics, 1985, 23, 25-33.	5.2	21
50	In Vitro Release and Intestinal Absorption of Physostigmine Salicylate from Submicron Emulsions. Journal of Pharmaceutical Sciences, 1991, 80, 643-647.	3.3	21
51	Synchronized release of sulpiride and sodium decanoate from HPMC matrices: a rational approach to enhance sulpiride absorption in the rat intestine. Pharmaceutical Research, 2000, 17, 1071-1076.	3.5	20
52	Pharmacologically active boranes. Pure and Applied Chemistry, 2006, 78, 1425-1453.	1,9	20
53	The relative roles of charge and a recognition peptide in luminal targeting of colorectal cancer by fluorescent polyacrylamide. European Journal of Pharmaceutical Sciences, 2012, 47, 904-913.	4.0	19
54	Pharmacokinetics of valpromide in dogs after various modes of administration. Biopharmaceutics and Drug Disposition, 1984, 5, 177-183.	1.9	18

#	Article	IF	Citations
55	Noncovalent inhibition of the serine proteases, α-chymotrypsin and trypsin by trifluoro(organo)borates. Organic and Biomolecular Chemistry, 2005, 3, 941-944.	2.8	18
56	The Metastatic Stage-dependent Mucosal Expression of Sialic Acid is a Potential Marker for Targeting Colon Cancer with Cationic Polymers. Pharmaceutical Research, 2008, 25, 379-386.	3.5	18
57	Direct formation of cyclobutenylphosphonates from 1-alkynylphosphonates and Cp2ZrCl2/2EtMgCl/2CuCl. Tetrahedron Letters, 2009, 50, 867-869.	1.4	18
58	Mo(CO)6-Mediated Intramolecular Pausonâ^'Khand Reaction of Substituted Diethyl 3-Allyloxy-1-Propynylphosphonates. Journal of Organic Chemistry, 2009, 74, 1029-1033.	3.2	18
59	A study of the effect on nucleophilic hydrolytic activity of pancreatic elastase, trypsin, chymotrypsin, and leucine aminopeptidase by boronic acids in the presence of arabinogalactan: a subsequent study on the hydrolytic activity of chymotrypsin by boronic acids in the presence of mono-, di-, and trisaccharides. Bioorganic Chemistry. 2003. 31. 464-474.	4.1	17
60	The effect of local attachment of cationized antioxidant enzymes on experimental colitis in the rat. Pharmaceutical Research, 2000, 17, 1077-1084.	3.5	15
61	A comparative study on the pharmacokinetics of valpramide after intravenous administration in dogs. Journal of Pharmacy and Pharmacology, 2011, 35, 607-609.	2.4	15
62	Enzymatic cleavage of disaccharide side groups in insoluble synthetic polymers: A new method for specific delivery of drugs to the colon. Biomaterials, 1993, 14, 483-490.	11.4	14
63	Synchronizing the release rates of salicylate and indomethacin from degradable chitosan hydrogel and its optimization by definitive screening design. European Journal of Pharmaceutical Sciences, 2018, 125, 102-109.	4.0	13
64	Synthesis of 3-hydroxy-1-alkenylboronates via phosphine stabilized borylzirconacyclopropenes. Chemical Communications, 2008, , 5589.	4.1	12
65	Protection of the Rat Jejunal Mucosa against Oxidative Injury by Cationized Superoxide Dismutase. Journal of Pharmaceutical Sciences, 1993, 82, 1285-1287.	3.3	11
66	Combined1H,13C and11B NMR and mass spectral assignments of boronate complexes of D-(+)-glucose,D-(+)-mannose, methyl-?-D-glucopyranoside, methyl-?-D-galactopyranoside and methyl-?-D-mannopyranoside. Magnetic Resonance in Chemistry, 2003, 41, 1015-1020.	1.9	11
67	Synchronized release of Doxil and Nutlin-3 by remote degradation of polysaccharide matrices and its possible use in the local treatment of colorectal cancer. Journal of Drug Targeting, 2011, 19, 859-873.	4.4	11
68	Enhanced stability of physostigmine salicylate in submicron o/ $\!w$ emulsion. International Journal of Pharmaceutics, 1990, 65, 169-175.	5.2	10
69	Controlled Drug Delivery. Progress in Clinical Biochemistry and Medicine, 1986, , 71-107.	0.5	10
70	Detecting a Secreted Gastric Cancer Biomarker Molecule by Targeted Nanoparticles for Real-Time Diagnostics. Pharmaceutical Research, 2012, 29, 983-993.	3.5	9
71	Absorption enhancement of captopril in the rat colon as a putative method for captopril delivery by extended release formulations. International Journal of Pharmaceutics, 1996, 143, 101-106.	5.2	8
72	Thermotropic behavior of celecoxib-loaded beta-casein micelles: relevance to the improved bioavailability. European Journal of Nanomedicine, 2015, 7, .	0.6	8

#	Article	IF	CITATIONS
73	The effect of linker type and recognition peptide conjugation chemistry on tissue affinity and cytotoxicity of charged polyacrylamide. Journal of Controlled Release, 2017, 257, 102-117.	9.9	8
74	A combined approach to control valproic acid release via novel delivery system of valpromide: A kinetic and pharmacokinetic study. Journal of Controlled Release, 1986, 4, 33-38.	9.9	7
75	Aminoalkylcarbamoylphosphonates reduce TNFα release from activated immune cells. Bioorganic and Medicinal Chemistry Letters, 2010, 20, 6518-6523.	2.2	7
76	Multi-modal detection of colon malignancy by NIR-tagged recognition polymers and ultrasound contrast agents. International Journal of Pharmaceutics, 2015, 478, 504-516.	5.2	7
77	Improved intestinal cannula for drug delivery studies in the dog. Journal of Pharmacological Methods, 1988, 19, 213-217.	0.7	6
78	Regional peptide uptake study in the rat intestinal mucosa: glatiramer acetate as a model drug. Pharmaceutical Research, 2002, 19, 832-837.	3.5	6
79	Celecoxib can induce cell death independently of cyclooxygenase-2, p53, Mdm2, c-Abl and reactive oxygen species. Anti-Cancer Drugs, 2006, 17, 609-619.	1.4	6
80	α-Amino boronates as cyanoborane complexes: crystal structure and inhibition properties for the serine proteases: α-chymotrypsin and trypsin. Applied Organometallic Chemistry, 2006, 20, 459-462.	3.5	6
81	Generalizing research findings for enhanced reproducibility: an approach based on verbal alternative representations. Scientometrics, 2021, 126, 4137-4151.	3.0	6
82	A new method for stability determination of semi-solid emulsions, using conductivity measurements. Colloids and Surfaces, 1981, 3, 221-231.	0.9	5
83	The effect of intestinal bacteria adherence on drug diffusion through solid films under stationary conditions. Pharmaceutical Research, 1997, 14, 503-507.	3.5	5
84	Adsorption of Cationized Bovine Serum Albumin onto Epithelial Crypt Fractions of the Rat Colon. Journal of Pharmaceutical Sciences, 2001, 90, 1516-1522.	3.3	4
85	Controlling the release rate of topotecan from PLGA spheres and increasing its cytotoxicity towards glioblastoma cells by co-loading with calcium chloride. International Journal of Pharmaceutics, 2021, 602, 120616.	5.2	4
86	Computerized Model for Evaluating the Kinetics of In Vitro Release of Valpromide from Controlled-Release Tablets Under Nonsink Conditions. Journal of Pharmaceutical Sciences, 1986, 75, 959-961.	3.3	3
87	A multifactorial analysis of complex pharmaceutical platforms: an application of design of experiments to targetable polyacrylamide and ultrasound contrast agents. Polymers for Advanced Technologies, 2015, 26, 898-905.	3.2	2
88	The Anti-Inflammatory Activity of a Novel Fused-Cyclopentenone Phosphonate and Its Potential in the Local Treatment of Experimental Colitis. Gastroenterology Research and Practice, 2015, 2015, 1-10.	1.5	2
89	Synchronizing the release rates of topotecan and paclitaxel from a self-eroding crosslinked chitosan – PLGA platform. International Journal of Pharmaceutics, 2022, 623, 121945.	5.2	2
90	Specific Detection of Gastric α-Antitrypsin by Immobilized Trypsin on PolyHEMA Films. Molecular Pharmaceutics, 2010, 7, 944-952.	4.6	1

#	Article	IF	CITATIONS
91	Molybdenum-Mediated Deconjugation of $\hat{l}\pm,\hat{l}^2$ -Unsaturated Fused-Cyclopentenone Phosphonates. Synthesis, 2012, 44, 1258-1262.	2.3	1
92	Nanoparticles in the Gastrointestinal Tract. Frontiers in Nanobiomedical Research, 2014, , 115-151.	0.1	1
93	A Generalization Approach to Reproducibility Claims. SSRN Electronic Journal, 2017, , .	0.4	1
94	The Effect of Adhesive Antioxidant Enzymes on Experimental Colitis in the Rat. ACS Symposium Series, 2000, , 78-89.	0.5	0